Dr. Renuka Gupta, MD
7215 Hanover Parkway · Greenbelt, MD 20770
4.9(35 Google reviews · 5 in past year)
Advanced Wellness Clinic · 6301 Ivy Lane · Greenbelt, MD 20770
5.0· 124 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Advanced Wellness Clinic is a hybrid direct primary care clinic in Greenbelt, Maryland. Its website describes on-demand, unlimited access to care without insurance, with transparent pricing, covering primary care, sick visits, medical weight loss, wellness injections and IV therapy, and says tirzepatide may be part of a medically supervised weight-loss program. The site names Banis Githinji, DNP. On Google it has a 5.0-star rating across 124 reviews dating back to 2025, with 53 posted in the past year. Reviewers most often mention the providers' knowledge and the staff, and 13 mention feeling cared for.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-02. Read the reviews themselves on the practice's Google listing.
Rated ★5.0 across 124 Google reviews. Of the 100 reviews we analyzed, 100 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
No negative reviews among those we analyzed.
Samwel O.★★★★★2026-09-02My experience at the clinic was by far the best I've received anywhere. From the admin staff to the doctor, my needs were fully met. I highly recommend this clinic!
Shirley E.★★★★★2026-08-24I just love the doctor she is so nice Listen to you and very patient. The staff was very nice.
Brenton F.★★★★★2026-08-22Everyone who are working in this office, I appreciate them all, I have never seen politeness in any business environment, like this office, such a wonderful group of professionals. Keep up the great work…
Denice S.★★★★★2026-08-05Great experience! They were very welcoming and the staff were professional. The team member Roxana was especially nice, and took the time to answer all of my questions.
Pauline P.★★★★★2026-07-31I had great experience with Dr. Banis she was professional kind and very supportive with no judgment she took the time to really listen and explained everything clearly and created a plan that will work for me I felt encouraged the staff are very pleasant and helpful the whole visit.Highly recommend!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
7215 Hanover Parkway · Greenbelt, MD 20770
4.9(35 Google reviews · 5 in past year)
6305 Ivy Lane · Greenbelt, MD 20770
5.0(3 Google reviews · 1 in past year)
7219 Hanover Parkway · Greenbelt, MD 20770
4.7(358 Google reviews · 11 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs